Molecular Templates, Inc. (MTEM)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -10.46 Million USD | 88.22% |
| 2022 | -88.87 Million USD | -10.99% |
| 2021 | -80.07 Million USD | 20.59% |
| 2020 | -100.84 Million USD | -43.14% |
| 2019 | -70.44 Million USD | -127.26% |
| 2018 | -30.99 Million USD | -73.69% |
| 2017 | -17.84 Million USD | 26.74% |
| 2016 | -24.36 Million USD | -190.47% |
| 2015 | 26.92 Million USD | 186.17% |
| 2014 | -31.25 Million USD | -20.09% |
| 2013 | -26.02 Million USD | -30.13% |
| 2012 | -19.99 Million USD | 33.42% |
| 2011 | -30.03 Million USD | -25.63% |
| 2010 | -23.9 Million USD | -12.12% |
| 2009 | -21.32 Million USD | -13.83% |
| 2008 | -18.73 Million USD | 42.09% |
| 2007 | -32.35 Million USD | 45.41% |
| 2006 | -59.25 Million USD | -27.34% |
| 2005 | -46.53 Million USD | -294.34% |
| 2004 | 23.94 Million USD | 388.19% |
| 2003 | -8.3 Million USD | -234.37% |
| 2002 | -2.48 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -50 Thousand USD | 99.07% |
| 2024 Q2 | -8.29 Million USD | -16492.0% |
| 2023 FY | -10.46 Million USD | 88.22% |
| 2023 Q3 | 5.13 Million USD | 143.75% |
| 2023 Q1 | 11.78 Million USD | 155.96% |
| 2023 Q2 | -11.74 Million USD | -199.64% |
| 2023 Q4 | -5.37 Million USD | -204.56% |
| 2022 FY | -88.87 Million USD | -10.99% |
| 2022 Q1 | -20.63 Million USD | -121.81% |
| 2022 Q2 | -23.83 Million USD | -15.55% |
| 2022 Q4 | -21.05 Million USD | 11.02% |
| 2022 Q3 | -23.66 Million USD | 0.72% |
| 2021 FY | -80.07 Million USD | 20.59% |
| 2021 Q2 | -14.91 Million USD | 43.35% |
| 2021 Q3 | -29.52 Million USD | -97.98% |
| 2021 Q4 | -9.3 Million USD | 68.5% |
| 2021 Q1 | -26.32 Million USD | -1.59% |
| 2020 FY | -100.84 Million USD | -43.14% |
| 2020 Q1 | -22.13 Million USD | -34.95% |
| 2020 Q2 | -29.91 Million USD | -35.14% |
| 2020 Q3 | -22.87 Million USD | 23.55% |
| 2020 Q4 | -25.91 Million USD | -13.32% |
| 2019 Q1 | -6.38 Million USD | 6.09% |
| 2019 Q3 | -38.26 Million USD | -307.01% |
| 2019 Q4 | -16.4 Million USD | 57.13% |
| 2019 FY | -70.44 Million USD | -127.26% |
| 2019 Q2 | -9.4 Million USD | -47.33% |
| 2018 Q3 | -5.07 Million USD | 49.31% |
| 2018 FY | -30.99 Million USD | -73.69% |
| 2018 Q4 | -6.79 Million USD | -33.87% |
| 2018 Q1 | -9.11 Million USD | -23.85% |
| 2018 Q2 | -10.01 Million USD | -9.85% |
| 2017 Q2 | 198 Thousand USD | 104.46% |
| 2017 Q1 | -4.44 Million USD | 10.48% |
| 2017 FY | -17.84 Million USD | 26.74% |
| 2017 Q4 | -7.36 Million USD | -25.38% |
| 2017 Q3 | -5.87 Million USD | -3064.65% |
| 2016 Q1 | -8.25 Million USD | -115.8% |
| 2016 Q4 | -4.96 Million USD | 5.23% |
| 2016 FY | -24.36 Million USD | -190.47% |
| 2016 Q3 | -5.23 Million USD | 11.36% |
| 2016 Q2 | -5.9 Million USD | 28.42% |
| 2015 Q2 | -8.94 Million USD | 7.01% |
| 2015 FY | 26.92 Million USD | 186.17% |
| 2015 Q4 | 52.25 Million USD | 871.55% |
| 2015 Q3 | -6.77 Million USD | 24.25% |
| 2015 Q1 | -9.61 Million USD | -27.33% |
| 2014 Q4 | -7.55 Million USD | 1.07% |
| 2014 FY | -31.25 Million USD | -20.09% |
| 2014 Q1 | -8.6 Million USD | -10.7% |
| 2014 Q2 | -7.46 Million USD | 13.3% |
| 2014 Q3 | -7.63 Million USD | -2.31% |
| 2013 FY | -26.02 Million USD | -30.13% |
| 2013 Q1 | -6.06 Million USD | -1.13% |
| 2013 Q2 | -6.96 Million USD | -14.98% |
| 2013 Q3 | -5.22 Million USD | 25.1% |
| 2013 Q4 | -7.77 Million USD | -48.93% |
| 2012 Q1 | -7.14 Million USD | 11.81% |
| 2012 Q3 | -3.98 Million USD | -38.3% |
| 2012 FY | -19.99 Million USD | 33.42% |
| 2012 Q2 | -2.88 Million USD | 59.68% |
| 2012 Q4 | -5.99 Million USD | -50.46% |
| 2011 FY | -30.03 Million USD | -25.63% |
| 2011 Q4 | -8.1 Million USD | -3.99% |
| 2011 Q1 | -7.39 Million USD | -20.76% |
| 2011 Q3 | -7.78 Million USD | -15.34% |
| 2011 Q2 | -6.75 Million USD | 8.67% |
| 2010 Q4 | -6.12 Million USD | -0.87% |
| 2010 Q1 | -5.75 Million USD | -4.85% |
| 2010 FY | -23.9 Million USD | -12.12% |
| 2010 Q2 | -5.95 Million USD | -3.53% |
| 2010 Q3 | -6.07 Million USD | -1.86% |
| 2009 FY | -21.32 Million USD | -13.83% |
| 2009 Q4 | -5.49 Million USD | -5.41% |
| 2009 Q3 | -5.2 Million USD | 4.53% |
| 2009 Q2 | -5.45 Million USD | -5.49% |
| 2009 Q1 | -5.17 Million USD | -6.09% |
| 2008 FY | -18.73 Million USD | 42.09% |
| 2008 Q3 | -4.65 Million USD | -214.83% |
| 2008 Q4 | -4.87 Million USD | -4.73% |
| 2008 Q2 | 4.05 Million USD | 178.65% |
| 2008 Q1 | -5.15 Million USD | 32.9% |
| 2007 Q3 | -6.94 Million USD | -185.78% |
| 2007 Q4 | -7.68 Million USD | -10.6% |
| 2007 FY | -32.35 Million USD | 45.41% |
| 2007 Q1 | -9.63 Million USD | 6.79% |
| 2007 Q2 | 8.09 Million USD | 184.05% |
| 2006 FY | -59.25 Million USD | -27.34% |
| 2006 Q1 | -14.89 Million USD | 7.58% |
| 2006 Q4 | -10.33 Million USD | 41.18% |
| 2006 Q3 | -17.56 Million USD | -6.68% |
| 2006 Q2 | -16.46 Million USD | -10.58% |
| 2005 Q4 | -16.11 Million USD | -34.35% |
| 2005 Q1 | -7.81 Million USD | -119.57% |
| 2005 Q2 | -10.61 Million USD | -35.79% |
| 2005 FY | -46.53 Million USD | -294.34% |
| 2005 Q3 | -11.99 Million USD | -13.01% |
| 2004 Q4 | 39.93 Million USD | 849.25% |
| 2004 FY | 23.94 Million USD | 388.19% |
| 2004 Q3 | -5.33 Million USD | 0.0% |
| 2003 FY | -8.3 Million USD | -234.37% |
| 2002 FY | -2.48 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | -2024.455% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -9.96% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 65.105% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 84.412% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | 33.939% |
| Better Therapeutics, Inc. | -38.26 Million USD | 72.646% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 75.125% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | 12.565% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 69.076% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 69.592% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 90.351% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | -419.584% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 69.219% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 77.709% |
| Innovation1 Biotech Inc. | -1.36 Million USD | -665.402% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 47.511% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | 25.514% |
| NexImmune, Inc. | -29.19 Million USD | 64.148% |
| Orgenesis Inc. | -53.63 Million USD | 80.487% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 79.596% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -13315.025% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 35.176% |
| Scopus BioPharma Inc. | -11.71 Million USD | 10.661% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 97.925% |
| Statera Biopharma, Inc. | -98.34 Million USD | 89.358% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -51.725% |
| Trevena, Inc. | -35.28 Million USD | 70.341% |
| Vaxxinity, Inc. | -58.28 Million USD | 82.043% |
| Vaccinex, Inc. | -22.88 Million USD | 54.267% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -899.639% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 79.354% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -44.1% |